Key result
In whole blood from healthy males, melagatran induced dose-dependent abnormalities in clotting profiles, which were significantly improved by rFVIIa and especially APCC.
Why the study?
Does rFVIIa or APCC improve haemostatic capacity in whole blood treated with the direct thrombin inhibitor melagatran?
Population
Whole blood from 30 healthy males
Comparison
In-vitro addition of melagatran followed by… vs Baseline/control without reversal agents
Design
Preclinical
Authors
Loading...
Should not yet change practice for reversing direct thrombin inhibitors; extends in-vitro evidence favoring APCC over rFVIIa.
Does rFVIIa or APCC improve haemostatic capacity in whole blood treated with the direct thrombin inhibitor melagatran?
In an in-vitro model, APCC was more effective than rFVIIa at reversing the anticoagulant effects of the direct thrombin inhibitor melagatran on whole blood clot formation.
Ingerslev et al. (2006) studied Healthy (n=30). Melagatran with rFVIIa or APCC vs. Baseline/no reversal agent was evaluated on Whole blood clotting profiles (clot initiation and maximum rate of clot propagation). In whole blood from healthy males, melagatran induced dose-dependent abnormalities in clotting profiles, which were significantly improved by rFVIIa and especially APCC.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: